Cargando…

Activity of Ceftolozane/tazobactam (C/T) and Ceftazidime/avibactam (CZA) against Extended-spectrum Β-lactamase (ESBL)-producing Enterobacteriaceae and Multidrug-resistant (MDR) Pseudomonas aeruginosa Isolates

BACKGROUND: Antibiotic resistance among Gram-negative bacterial pathogens is a serious public health threat underscored by a diminishing antibiotic development pipeline. This study evaluated the in vitro activity of two new β-lactam/β-lactamase inhibitors, C/T and CZA, against the problematic pathog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirsch, Elizabeth B, Zucchi, Paola, Cheung, Nicole, Krevolin, Kyle, Emery, Christopher, Bias, Tiffany
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631517/ http://dx.doi.org/10.1093/ofid/ofx163.927

Ejemplares similares

2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR) Pseudomonas aeruginosa
por: Shah, Sunish, et al.
Publicado: (2023)

1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF)
por: Lasko, Maxwell J, et al.
Publicado: (2020)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021)

Comparative in vitro Activities of Ceftazidime–Avibactam and Ceftolozane-tazobactam Against Characterized β-Lactamase-producing Pseudomonas aeruginosa
por: Lin, Lynn-Yao, et al.
Publicado: (2017)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
por: Gangcuangco, Louie Mar, et al.
Publicado: (2016)

Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar
por: Ahmed, Mazen A. Sid, et al.
Publicado: (2022)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
por: Cortazzo, Venere, et al.
Publicado: (2022)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
por: Brink, Adrian J., et al.
Publicado: (2022)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
por: Criscuolo, Marianna, et al.
Publicado: (2020)

1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2020)

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients
por: Sader, Helio S, et al.
Publicado: (2021)

Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
por: Huang, Weihua, et al.
Publicado: (2020)

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
por: Gonzalez, Mark D., et al.
Publicado: (2017)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014)

718. Activity of Ceftolozane–Tazobactam and Ceftazidime–Avibactam Against Clinical P. aeruginosa Isolates Collected in United States and Canada—SMART 2018
por: Lob, Sibylle, et al.
Publicado: (2019)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
por: Weber, C., et al.
Publicado: (2022)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Papadomanolaki, Arhodoula, et al.
Publicado: (2022)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
por: Cultrera, Rosario, et al.
Publicado: (2020)

Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
por: Meschiari, Marianna, et al.
Publicado: (2020)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) Pseudomonas aeruginosa: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
por: Meschiari, Marianna, et al.
Publicado: (2021)

First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
por: Rahimzadeh, Mohammad, et al.
Publicado: (2020)

The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M., et al.
Publicado: (2021)

706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing Klebsiella pneumoniae (Kp)
por: Jones, Chelsea, et al.
Publicado: (2018)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
por: Contreras-Gómez, María José, et al.
Publicado: (2022)

1109. A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS)
por: Shields, Ryan K, et al.
Publicado: (2023)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

The Effect of Clinical Concentrations of Meropenem (MEM), Ceftolozane/tazobactam (C/T), and Ceftazidime/avaibactam (CZA) on Time to Detection (TTD) and Growth of Pseudomonas aeruginosa (PSA) in bioMerieux BacT/ALERT(®)FA Plus Blood Culture (BC) Bottles
por: Grupper, Mordechai, et al.
Publicado: (2017)

1594. Ceftolozane–Tazobactam Demonstrates Higher In Vitro Susceptibility than Ceftazidime–Avibactam Against Pseudomonas aeruginosa Isolated from Respiratory Tract of Adult Cystic Fibrosis Patients
por: Nolan, Patrick James, et al.
Publicado: (2019)

Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report
por: Alamri, Aisha M, et al.
Publicado: (2020)

1385. Efficacy of Ceftazidime–Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-Lactamase Producing-Enterobacteriaceae (MBL)
por: Lodise, Thomas P, et al.
Publicado: (2018)

233. Safety of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)
por: Lodise, Thomas, et al.
Publicado: (2022)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
por: Patel, Twisha S, et al.
Publicado: (2019)

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients
por: Marner, Michael, et al.
Publicado: (2023)

Association of bla(VIM-2), bla(PDC-35), bla(OXA-10,) bla(OXA-488) and bla(VEB-9) β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa
por: Sid Ahmed, Mazen A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_avnprlgotqje552n4mbaetrqcg